Display options
Cite
Schöfl C, Lübben G. Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice. Clin Drug Investig. 2003;23(11):725-34doi: 10.2165/00044011-200323110-00005.
Schöfl, C., & Lübben, G. (2003). Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice. Clinical drug investigation, 23(11), 725-34. https://doi.org/10.2165/00044011-200323110-00005
Schöfl, Christof, and Lübben, Georg. "Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice." Clinical drug investigation vol. 23,11 (2003): 725-34. doi: https://doi.org/10.2165/00044011-200323110-00005
Schöfl C, Lübben G. Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice. Clin Drug Investig. 2003;23(11):725-34. doi: 10.2165/00044011-200323110-00005. PMID: 17536886.
Copy Download .nbib Format: NLM
Share it on

Clin Drug Investig. 2003;23(11):725-34. doi: 10.2165/00044011-200323110-00005.

Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice.

Clinical drug investigation

Christof Schöfl, Georg Lübben

Affiliations

  1. Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany.

PMID: 17536886 DOI: 10.2165/00044011-200323110-00005

Abstract

OBJECTIVE: To evaluate the efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus treated in general practice settings.

DESIGN AND SETTING: This was a postmarketing surveillance study involving 2537 primary-care physicians throughout Germany.

PATIENTS AND INTERVENTIONS: A total of 8760 patients with type 2 diabetes were treated with pioglitazone 15 or 30mg once daily and followed for 16 weeks.

RESULTS: Treatment with pioglitazone 15 or 30mg once daily was associated with a reduction in both fasting plasma glucose (mean 50.1 mg/dL) and glycosylated haemoglobin (HbA(1c)) [mean 1.4%] compared with baseline. The proportion of patients with 'normal' fasting glucose levels (70-110 mg/dL) increased from 2.3% at baseline to 24.2% at the final evaluation. Pioglitazone therapy was associated with a reduction in levels of triglycerides, total cholesterol and low-density lipoprotein (LDL)-cholesterol, and an increase in levels of high-density lipoprotein (HDL)-cholesterol. The proportion of patients at high risk of developing vascular complications decreased progressively during pioglitazone therapy according to a number of parameters.

CONCLUSIONS: Pioglitazone was well tolerated and effective in improving glycaemic control and lipid profiles in patients with type 2 diabetes. Pioglitazone may be effective in reducing the risk of vascular complications of diabetes.

References

  1. Curr Med Res Opin. 2001;17(3):166-89 - PubMed
  2. Clin Ther. 2001 Nov;23(11):1792-823; discussion 1791 - PubMed
  3. Int J Clin Pract Suppl. 2001 Sep;(121):27-31 - PubMed
  4. Clin Ther. 2000 Dec;22(12):1395-409 - PubMed
  5. J Clin Endocrinol Metab. 2002 Dec;87(12):5503-6 - PubMed
  6. Int J Clin Pract. 2002 May;56(4):251-7 - PubMed
  7. Lancet. 1998 Sep 12;352(9131):837-53 - PubMed
  8. Health Technol Assess. 2001;5(19):1-61 - PubMed
  9. J Clin Invest. 1995 Jul;96(1):354-60 - PubMed
  10. Horm Metab Res. 2002 Oct;34(10):589-95 - PubMed
  11. Diabetes Care. 2000 Nov;23(11):1605-11 - PubMed
  12. Diabetes Care. 2002 Apr;25(4):708-11 - PubMed
  13. Endocr Pract. 2001 May-Jun;7(3):162-9 - PubMed
  14. N Engl J Med. 1993 Sep 30;329(14 ):977-86 - PubMed
  15. Exp Clin Endocrinol Diabetes. 1998;106(4):240-69 - PubMed
  16. Diabetologia. 2002 Jul;45(7):S5-12 - PubMed
  17. Pharmacoeconomics. 2002;20 Suppl 1:31-42 - PubMed
  18. JAMA. 2001 Sep 12;286(10):1195-200 - PubMed
  19. Clin Ther. 2002 Mar;24(3):378-96 - PubMed
  20. Diabet Med. 2002 Jul;19 Suppl 4:1-5 - PubMed
  21. Am J Med. 2001 Jul;111(1):10-7 - PubMed
  22. Diabetes Care. 2003 Mar;26(3):917-32 - PubMed

Publication Types